Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of NICE’s Late Stage Assessments on the attractiveness of the UK for inward investment from medtech companies.

The Department commissioned the National Institute for Health and Care Excellence (NICE) to undertake Late-Stage Assessments (LSAs) to help commissioners, clinicians, and patients identify the most effective products that offer the best value for the National Health Service. LSAs benefit health technology manufacturers by giving all manufacturers a transparent, robust, and evidence-based process for demonstrating the added value of their products.